SCOTUS judges favour fact-specific approach to landmark ‘skinny label’ dispute

Hatch-Waxman & Biologics Chair Chad Landmon discusses how U.S. Supreme Court justices appear inclined to take a fact-specific approach in the Hikma v. Amarin “skinny label” dispute rather than establishing a broad new legal standard for induced patent infringement. He notes that the Court’s questioning suggests a focus on applying existing inducement principles and evaluating the totality of a company’s conduct, rather than treating compliant labeling alone as determinative. Landmon highlights that the outcome could still have significant implications for generic drug makers, particularly in how courts assess intent and marketing practices in relation to patented uses.